Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: reply.

We provide here a new set of data supporting the involvement of multiple platelet receptors in CpG ODN platelet activating effects. We observed some sequence-specific features of platelet responses to phosphorothioate-modified CpG ODNs types A, B, and C that could be useful for future development of safe therapeutic CpG ODNs. Additional investigations are needed in order to further delineate these sequence specificities, and to address the importance of higher-order structures, as well as of possible interactions with cofactors for the effects of CpG ODN on platelets.